CLO trio priced but Omicron effect yet to show up in pricing

© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

CLO trio priced but Omicron effect yet to show up in pricing

Blood tube for test detection of virus Covid-19 Omicron Variant with positive result on papers document.

Three recent European CLO pricings reflect none of the recent market volatility over the new omicron variant of the coronavirus. But that could change soon, believes one investor

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login
  • 4,000 annual insights
  • 700+ notes and long-form analyses
  • European securitization issuance database
  • Daily newsletters across markets and asset classes
  • 1 weekly securitization podcast
Gift this article